

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

Test Report Status

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

<u>Final</u>

PATIENT ID: CHAUF180280181

Biological Reference Interval Units

AGE: 42 Years ABHA NO: ACCESSION NO: 0181VJ000365 SEX : Female

RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31 DRAWN:

Results

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

METHON HEEL FULL RODY HEALTH CHECKUP ABOVE 40FEMALE BLOOD COUNTS, EDTA WHOLE BLOOD METHOD: SIS-HEMMOGLOBIN DETECTION METHOD RED BLOOD CELL COUNT 4.37 3.8 - 4.8 mil/μL METHOD: SIS-HEMMOGLOBIN DETECTION METHOD METHOD: SIS-HEMMOGLOBIN DETECTION 4.37 3.8 - 4.8 mil/μL METHOD: HYDROCYMAMIC FOCUSING BY DIC DETECTION METHOD: FLUORESCENCE FLOW CYTOMETRY METHOD: CALCULATIVE PROBABOLE BEIGHT DETECTION METHOD METHOD: CALCULATIVE PROBABOLE ALC METHOD: CALCULATIVE PROBABOLE ALC METHOD: CALCULATED FROM THE BEC & HGS MEAN CORPUSCULAR HOSO METHOD: CALCULATED FROM THE BEC & HGS MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE BEC & HGS MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE BEC & HGS MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE BEC & HGS MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE HGS & HCT METHOD: CALCULATED FROM THE HGS & HCT METHOD: CALCULATED FROM PACHELET HEMOGLOBIN METHOD: CALCUL					
HEMOGLOBIN 10.00	MEDI WHEEL FULL BODY HEALTH CHECKUP	ABOVE 40FEMAL	E		
RED BLOOD CELL COUNT 4.37 3.8 - 4.8 mIl/μL METHOD: HYDROCDYNAMIC FOOUSING BY DE DETECTION 8.43 4.0 - 10.0 thou/μL WHITE BLOOD CELL COUNT 8.43 4.0 - 10.0 thou/μL METHOD: FLUORESCENCE FLOW CYTOMETRY 150 - 410 thou/μL METHOD: HYDROCDYNAMIC FOOUSING BY DE DETECTION 359 150 - 410 thou/μL METHOD: HYDROCDYNAMIC FOOUSING BY DE DETECTION 8 150 - 410 thou/μL METHOD: HYDROCDYNAMIC FOOUSING BY DE DETECTION 8 150 - 410 thou/μL METHOD: CHARD FROM PROBUSED FROM BE RED RED RED RED RED RED RED RED RED RE	BLOOD COUNTS, EDTA WHOLE BLOOD				
RED BLOOD CELL COUNT 8.437 3.8 - 4.8 mil/µL METHOD: HORDOWAMIC POCUSING BY DC DETECTION WHITE BLOOD CELL COUNT 8.43 4.0 - 10.0 blou/µL METHOD: FLUGRESSENCE FLOW CYTOMETRY PLATELET COUNT 359 150 - 410 blou/µL METHOD: HORDOWAMIC POCUSING BY DC DETECTION METHOD: HORDOWAMIC POCUSING BY DC DETECTION METHOD: CHUNCHAMIC POCUSING BY DC DETECTION RED AND PLATELET INDICES HEMATOCRIT 94.5 Low 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 78.9 Low 36.0 - 46.0 % METHOD: CALCULATED FROM RSC & HCE MEAN CORPUSCULAR HGB. 22.9 Low 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RSC & HGB MEAN CORPUSCULAR HEMOGLOBIN 29.0 Low 31.5 - 34.5 gg/dL CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX MENDED: CALCULATED FROM THE HGB & HCT MENTZER INDEX MENDED: CALCULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 High 11.6 - 14.0 % METHOD: CALCULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 B.8 10.9 fL METHOD: CALCULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 20.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 20.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 20.4 B.8 10.9 fL METHOD: CALCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN CORPUSCULATED FROM PSC SIZE DISTRIBUTION CURVE MEAN CORPOSITION WITH LIGHT SCATTERING LYMPHOCYTES 20.4 C.9	HEMOGLOBIN	10.0	Low	12.0 - 15.0	g/dL
MHITTE BLOOD CELL COUNT 8.43 4.0 - 10.0 thou/jul METHOD: FLUORESCENCE FLOW CYTOMETRY METHOD: FLUORESCENCE FLOW CYTOMETRY METHOD: FLUORESCENCE FLOW CYTOMETRY METHOD: FLOORESCENCE FLOW CYTOMETRY METHOD: FLOORESCENCE FLOW CYTOMETRY METHOD: FLOORESCENCE FLOW CYTOMETRY METHOD: FLOORESCENCE FLOW CYTOMETRY METHOD: FOR AND PLATELET COUNT 359 150 - 410 thou/jul METHOD: CALOULATICE FROM RSC & DETECTION METHOD METHOD: CAMULATIVE POLISE HEIGHT DETECTION METHOD METHOD: CALOULATED FROM RSC & HCT MEAN CORRUSCULAR WOL 78.9 LOW 30.0 - 101.0 FL METHOD: CALOULATED FROM RSC & HCT MEAN CORRUSCULAR HGB. 22.9 LOW 27.0 - 32.0 Pg METHOD: CALOULATED FROM THE HBC & HGB MEAN CORRUSCULAR HENGCLOBIN 29.0 LOW 31.5 - 34.5 Pg/dL CONCENTRATION METHOD: CALOULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 High 11.6 - 14.0 % METHOD: CALOULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 FL METHOD: CALOULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 FL METHOD: CALOULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 % METHOD: ELOW CYTOMETRY WITH LIGHT SCATTERING ASSOLUTE NEUTROPHIL COUNT 4.27 2.0 - 7.0 thou/jul METHOD: ELOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 % METHOD: ELOW CYTOMETRY WITH LIGHT SCATTERING ASSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/jul METHOD: ELOW CYTOMETRY WITH LIGHT SCATTERING	METHOD: SLS-HEMOGLOBIN DETECTION METHOD				
MITTE BLOOD CELL COUNT 8.43 4.0 - 10.0 thou/μL METHOD: FUNORESCENCE FLOW CYTOMETRY PLATELET COUNT 359 150 - 410 thou/μL METHOD: HYDROD VMAMIC FOCUSING BY DC DETECTION RETHOD: HYDROD VMAMIC FOCUSING BY DC DETECTION RETHOD: CHYDROD VMAMIC FOCUSING BY DC DETECTION METHOD: CHYDROD VMAMIC FOCUSING BY DC DETECTION METHOD: CHYDROD VMAMIC FOCUSING BY DC DETECTION METHOD: CALCULATED FROM RECENTRY MEAN CORPUSCULAR VOL 78.9 Low 83.0 - 101.0 place METHOD: CALCULATED FROM THE BRG & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE BG & HGT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 High 11.6 - 14.0 place METHOD: CALCULATED FROM RSC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 place METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LOW CYTOMETRY WITH LIGHT SCATTERING LOW CYTOMETRY WITH LIGHT SCATTERING LOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	RED BLOOD CELL COUNT	4.37		3.8 - 4.8	mil/μL
PLATELET COUNT 359 150 - 410 thou/µL METHOD: HVDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATELET INDICES HEMATOCRIT 34.5 Low 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORRUSCULAR VOL 78.9 Low 27.0 - 32.0 fl. METHOD: CALCULATED FROM THE RBC & HGB MEAHO CORRUSCULAR HGB. 22.9 Low 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAH CORRUSCULAR HEMOGLOBIN 29.0 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 Hgb 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
PLATE LET COUNT 359 150 - 410 thou/µL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATE LET INDICES HEMATOCRIT 34.5 Low 36.0 - 46.0 % METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD METHOD : CALCULATED FROM RBC & HCT	WHITE BLOOD CELL COUNT	8.43		4.0 - 10.0	thou/µL
RBC AND PLATELET INDICES HEMATOCRIT 34.5 Low 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR VOL 78.9 Low 27.0 - 32.0 pg METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 22.9 Low 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 29.0 Low 31.5 - 34.5 gg/dL CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 High 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS SEGMENTED NEUTROPHIL COUNT 24.27 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD: FLUORESCENCE FLOW CYTOMETRY				
RBC AND PLATELET INDICES HEMATOCRIT	PLATELET COUNT	359		150 - 410	thou/µL
HEMATOCRIT METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD 78.9 Low 83.0 - 101.0 FL METHOD : CALCULATED FROM RBC & HCT METHOD : CALCULATED FROM RBC & HCT METHOD : CALCULATED FROM RBC & HCT METHOD : CALCULATED FROM MER RBC & HGB METHOD : CALCULATED FROM MER RBC & HGB METHOD : CALCULATED FROM MER RBC & HGB METHOD : CALCULATED FROM MER RBC & HGB METHOD : CALCULATED FROM MER RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 29.0 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD : CALCULATED FROM THE HGB & HCT METHOD : CALCULATED FROM THE HGB & HCT METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR THE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR THE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR THE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR THE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOR THE METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 28 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 2.38 1.0 - 3.0 thou/μL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/μL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 1.8 ** **M	METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 78.9 Low 83.0 - 101.0 fL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 22.9 Low 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 29.0 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 High 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.27 2.0 - 7.0 thou/μL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/μL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 1.8	RBC AND PLATELET INDICES				
MEAN CORPUSCULAR VOL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. METHOD: CALCULATED FROM THE RBC & HGB METHOD: CALCULATED FROM THE RBC & HGB METHOD: CALCULATED FROM THE RBC & HGB METHOD: CALCULATED FROM THE HGB & HCT METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD: CALCULATED FROM PACTELET COUNT & PLATELET HEMATORITY WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERIN	HEMATOCRIT	34.5	Low	36.0 - 46.0	%
METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. METHOD: CALCULATED FROM THE RBC & HGB METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT METHOD: CALCULATED FROM THE HGB & HCT METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 ABSOLUTE NEUTROPHIL COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE COUNT ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE LYMPHOCYTE RATIO (NLR) 1.8	METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR HGB. METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATICAL TOLUME METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	MEAN CORPUSCULAR VOL	78.9	Low	83.0 - 101.0	fL
METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 ABSOLUTE NEUTROPHIL COUNT AL27 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE LYMPHOCYTE RATIO (NLR) 1.8	METHOD: CALCULATED FROM RBC & HCT				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM PBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME METHOD: CALCULATED FROM PBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	MEAN CORPUSCULAR HGB.	22.9	Low	27.0 - 32.0	pg
CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 18.1 RED CELL DISTRIBUTION WIDTH 16.1 METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE RATIO (NLR) 1.8	METHOD: CALCULATED FROM THE RBC & HGB				
RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATORITY WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	CONCENTRATION	29.0	Low	31.5 - 34.5	g/dL
METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.27 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	MENTZER INDEX	18.1			
METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.4 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.27 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	RED CELL DISTRIBUTION WIDTH	16.1	High	11.6 - 14.0	%
MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATORITY WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE LYMPHOCYTE COUNT NETHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT NETHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8			-		
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCIT WBC DIFFERENTIAL COUNT - NLR SEGMENTED NEUTROPHILS 51 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.27 2.0 - 7.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 28 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	MEAN PLATELET VOLUME	10.4		6.8 - 10.9	fL
SEGMENTED NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8		HEMATOCRIT			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	WBC DIFFERENTIAL COUNT - NLR				
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	SEGMENTED NEUTROPHILS	51		40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8		51			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	ABSOLUTE NEUTROPHIL COUNT	4.27		2.0 - 7.0	thou/u1
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8					2.53, [2
ABSOLUTE LYMPHOCYTE COUNT 2.38 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	LYMPHOCYTES	28		20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8	ABSOLUTE LYMPHOCYTE COUNT	2.38		1.0 - 3.0	thou/μL
· · ·	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS 17 High 1 - 6 %	NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8			
	EOSINOPHILS	17	High	1 - 6	%



Page 1 Of 13



ACROFEMI HEALTHCARE LTD (MEDI WHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years SEX: Female ABHA NO: ACCESSION NO: 0181VJ000365

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

CLIENT PATIENT ID: REFERRING DOCTOR: SELF

Test Report Status	<u>Final</u>	Results		Biological Reference Inte	rval Units
METHOD - ELOW OVERNETE	WANTE LACUT COATTERING				
ABSOLUTE EOSINOPH	RY WITH LIGHT SCATTERING	1.43	High	0.02 - 0.50	thou/µL
		1.43	riigii	0.02 - 0.30	αιοά/με
MONOCYTES	RY WITH LIGHT SCATTERING	4		2 - 10	%
	RY WITH LIGHT SCATTERING	4		2 - 10	70
ABSOLUTE MONOCYTE		0.34		0.2 - 1.0	thou/µL
	RY WITH LIGHT SCATTERING	0.34		0.2 - 1.0	шои/µг
DIFFERENTIAL COUNT		EDTA SMEAR			
	PERFORMED ON.	EDTA SPIEAK			
MORPHOLOGY					
RBC		MICROCYTOSIS	& ANISOC	YTOSIS	
WBC		NORMAL MORPH	OLOGY		
METHOD : MICROSCOPIC EX	XAMINATION				
PLATELETS		ADEQUATE			
ERYTHRO SEDIMENT	TATION RATE, BLOOK				
SEDIMENTATION RATE	(ESR)	06		0 - 20	mm at 1 hr
METHOD : WESTERGREN ME	ETHOD				
GLYCOSYLATED HEM	IOGLOBIN, EDTA WH	OLE BLOOD			
GLYCOSYLATED HEMO	GLOBIN (HBA1C)	5.9	High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
	C.C.	122.6	⊔iab	< 116.0	ma/dl
MEAN PLASMA GLUCO: METHOD : CALCULATED PAR		122.6	nign	< 116.0	mg/dL
GLUCOSE, FASTING,		400	110-1-	N 175 00	
GLUCOSE, FASTING, P	LASMA	108	Hign	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD: ENZYMATIC REFE	ERENCE METHOD WITH HEXOK	INASE			
GLUCOSE, POST-PRA	ANDIAL, PLASMA				
GLUCOSE, POST-PRAN	DIAL, PLASMA	95		70 - 139	mg/dL
METHOD : ENZYMATIC REFE	ERENCE METHOD WITH HEXOK	INASE			







CLIENT'S NAME AND ADDRESS: ACROFEMI HEALTHCARE LTD (MEDI WHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years SEX: Female ABHA NO: ACCESSION NO: 0181VJ000365

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
CHOLESTEROL	200		Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY TRIGLYCERIDES	150		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY HDL CHOLESTEROL	34	Low	Low HDL Cholesterol <40	mg/dL
METHOD: ENZYMATIC, COLORIMETRIC CHOLESTEROL LDL	136	High	High HDL Cholesterol >/= 60 Adult levels: Optimal < 100 Near optimal/above optimal: 1 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY NON HDL CHOLESTEROL	166	High	Desirable : < 130 Above Desirable : 130 - 159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
CHOL/HDL RATIO	5.9	High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	4	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN LIVER FUNCTION PROFILE, SERUM	30.0		< OR = 30.0	mg/dL
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.23		Upto 1.2	mg/dL
BILIRUBIN, DIRECT BILIRUBIN, INDIRECT	0.11 0.12		< 0.30 0.1 - 1.0	mg/dL mg/dL



Page 3 Of 13



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID:

CHAUF180280181

DRAWN:

ACCESSION NO: 0181VJ000365

AGE: 42 Years

SEX: Female

RECEIVED: 08/10/2022 09:00:07

ABHA NO:

REPORTED: 12/10/2022 16:09:31

REFERRING DOCTOR: SELF

CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	e Interval Units
TOTAL BROTEIN	7.4		60.00	- (-)
TOTAL PROTEIN METHOD: COLORIMETRIC	7.4		6.0 - 8.0	g/dL
ALBUMIN	4.5		3.97 - 4.94	q/dL
METHOD : COLORIMETRIC	5		0.57 1.51	gjac
GLOBULIN	2.9		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.6		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	31		< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	35		< OR = 35	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	81		35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	44	High	0 - 40	U/L
LACTATE DEHYDROGENASE	195		125 - 220	U/L
METHOD: UV ABSORBANCE				
SERUM BLOOD UREA NITROGEN				
BLOOD UREA NITROGEN	9		6 - 20	mg/dL
METHOD: ENZYMATIC ASSAY				
CREATININE, SERUM				
CREATININE	0.71		0.5 - 0.9	mg/dL
METHOD: COLORIMETRIC				
BUN/CREAT RATIO				
BUN/CREAT RATIO	12.68		8.0 - 15.0	
URIC ACID, SERUM				
URIC ACID	4.1		2.4 - 5.7	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.4		6.0 - 8.0	g/dL
METHOD: COLORIMETRIC				
ALBUMIN, SERUM				
ALBUMIN	4.5		3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN	0.0			
GLOBULIN	2.9		2.0 - 3.5	g/dL





CLIENT'S NAME AND ADDRESS: ACROFEMI HEALTHCARE LTD (MEDI WHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years SEX: Female ABHA NO: ACCESSION NO: 0181VJ000365

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Inte	rval Units
FLEATBOLDEEC (NA /V/CL) CERUM			
ELECTROLYTES (NA/K/CL), SERUM	100	100 145	
SODIUM	138	136 - 145	mmol/L
POTASSIUM	4.68	3.5 - 5.1	mmol/L
CHLORIDE	105	98 - 107	mmol/L
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
METHOD: VISUAL INSPECTION			
APPEARANCE	CLEAR		
METHOD: VISUAL INSPECTION			
SPECIFIC GRAVITY	1.025	1.003 - 1.035	
METHOD: IONIC CONCENTRATION METHOD			
CHEMICAL EXAMINATION, URINE			
PH	5.5	4.7 - 7.5	
METHOD: DOUBLE INDICATOR PRINCIPLE			
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID			
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD: GLUCOSE OXIDASE PEROXIDASE			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD: PEROXIDASE			
UROBILINOGEN	NORMAL	NORMAL	
METHOD: MODIFIED EHRLICH REACTION	NOT DETECTED	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	1-2	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	NOT DETERME	NOT DETECTED	aune.
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
CASTS	NOT DETECTED		



Page 5 Of 13



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MÈHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID : CHAUF180280181

ACCESSION NO: 0181VJ000365 AGE: 42 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
METHOD: MICROSCOPIC EXAMINATION				
CRYSTALS	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION				
BACTERIA	NOT DETECTED		NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION				
YEAST	NOT DETECTED		NOT DETECTED	
THYROID PANEL, SERUM				
Т3	77.8	Low	80 - 200	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE				
T4	9.36		5.1 - 14.1	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE				
TSH 3RD GENERATION	4.170		0.27 - 4.2	μIU/mL
METHOD: ELECTROCHEMILUMINESCENCE				
PAPANICOLAOU SMEAR				
TEST METHOD	CONVENTIONAL G	YNEC CY	TOLOGY	
METHOD: MICROSCOPIC EXAMINATION				
SPECIMEN TYPE	P-1163/22			
	TWO LINCTAINED	СЕВУЛСА	AL SMEARS RECEIVED	
METHOD: MICROSCOPIC EXAMINATION	TWO ONSTAINED	CLKVICA	IL SPILANS NECEIVED	
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY			
SPECIMEN ADEQUACY	SATISFACTORY			
METHOD: PAP STAIN & MICROSCOPIC EXAMINATION				
MICROSCOPY	THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, FEW PARABASAL CELLS, FEW CLUSTERS OF ENDOCERVICAL CELLS IN THE BACKGROUND OF FEW POLYMORPHS.			
METHOD : PAP STAIN				
INTERPRETATION / RESULT	NEGATIVE FOR IN	FRAEPIT	HELIAL LESION OR MALIC	GNANCY
METHOD: PAP STAIN & MICROSCOPIC EXAMINATION				

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A





ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

8800465156

THANE, 400602 MAHARASHTRA, INDIA

S.K. Tower, Hari Niwas, LBS Marg

SRL Ltd

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

PATIENT ID:

CHAUF180280181

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

ACCESSION NO: 0181VJ000365 AGE: 42 Years SEX: Female ABHA NO:

RECEIVED: 08/10/2022 09:00:07 12/10/2022 16:09:31 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units Final

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO 2 D ECHO :- MILD TR

ECG

ECG WITHIN NORMAL LIMITS

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS DONOMAMMOGRAPHY: - SIMPLE CYST IN LEFT BREAST AS DESCRIBED.

MEDICAL HISTORY

RELEVANT PRESENT HISTORY HYPOTHYROID SINCE 2 YEARS

RELEVANT PAST HISTORY PAST H/O GOITER , THYROIDECTOMY 2 YEARS BACK.

RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING / NO

ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) REGULAR :- 28-32/ 5 DAYS

LMP (FOR FEMALES) 30/09/2022 **OBSTETRIC HISTORY (FOR FEMALES)** 2FTND,A2,L2 LCB (FOR FEMALES) 20 YEARS BACK. RELEVANT FAMILY HISTORY FATHER: - DIABETES HISTORY OF MEDICATIONS TAB: - THYRONORM

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.58 mts WEIGHT IN KGS. 73 Kgs

BMI 29 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS **OVERWEIGHT BUILT / SKELETAL FRAMEWORK AVERAGE**





ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd S.K. Tower,Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID : CHAUF180280181

ACCESSION NO: 0181VJ000365 AGE: 42 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Un	ts
--	----

FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL BREAST (FOR FEMALES) NORMAL TEMPERATURE NORMAL

PULSE 82/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 130/80 MM HG mm/Hg

(SUPINE)

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL

MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER NOT PALPABLE SPLEEN NOT PALPABLE

HERNIA ABSENT

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL





ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: customercare.thane@srl.in

SRL Ltd

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

ACCESSION NO: 0181VJ000365 AGE: 42 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 08/10/2022 09:00:07 REPORTED: 12/10/2022 16:09:31

CLIENT PATIENT ID: REFERRING DOCTOR: SELF

Test Report Status <u>Final</u>	Results	Biological Reference Interval Un	iits
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			
SPINE	NORMAL		
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	REDUCED VISUAL ACU	П Ү 6/24	
DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCED VISUAL ACU	П Ү 6/24	
DISTANT VISION RIGHT EYE WITH GLASSES	WITH GLASSES NORMA	AL	
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORM	AL	
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMI	Т	
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMI	Т	
COLOUR VISION	NORMAL		
SUMMARY			
RELEVANT HISTORY	NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS	OVERWEIGHT :- BMI 2	9	
REMARKS / RECOMMENDATIONS	ADVICE:- 1)TO DO S.IRON PROF 2)LOW FAT,LOW CALO DIET.	ILE. RIE, LOW CARBOHYDRATE, HIGH FIBRE DII	ET,IRON
	3)REGULAR EXERCISE.	REGULAR WALK FOR 30-40 MIN DAILY.	
	AND EXERCISE.	LE, BLOOD SUGAR AFTER 3 MONTHS OF D MOGRAPHY TO MONITOR CYSTS IN LEFT BR	

6)SUGGEST MAMMOGRAPHY.





CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years ACCESSION NO: 0181VJ000365 SEX: Female ABHA NO:

12/10/2022 16:09:31 RECEIVED: 08/10/2022 09:00:07 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u> Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE **ULTRASOUND ABDOMEN**

ULTRASOUND ABDOMEN

GRADE I FATTY LIVER

Interpretation(s)
BLOOD COUNTS,ED TA WHOLE BLOODThe cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. WBC DIFFERENTIAL COUNT - NLR-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHRO SEDIMENTATION RATE, BLOODErythrocyte sedimentation rate (ESR) is a non - specific phenomena and is dinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0 -1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
 3. The reference for the adult reference range is "Practical Haematology by Dage and Lewis, 10th Edition"

GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-

Glycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood, the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased

glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia

or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.
Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.

"Targets should be individualized, More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations."

References

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R. Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006,
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:

Pre-diabetics: 100 - 125 mg/dL

Diabetic: > or = 126 mg/dL GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when





CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years ABHA NO: ACCESSION NO: 0181VJ000365 SEX: Female

12/10/2022 16:09:31 RECEIVED: 08/10/2022 09:00:07 REPORTED: DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units Final

there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin m ay be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal musde, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,musdes, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalada, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson's disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles. The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also ariu pariureas. Curiniuons that increase serum GGT are obstructive liver disease, nigh alcohol consumption and use of enzyme-induding drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Hum an serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

SERUM BLOOD UREA NITRÓGEN-

Causes of Increased levels Pre renal

- High protein diet. Increased protein catabolism. GI haemorrhage. Cortisol. Dehydration. CHF Renal
- Renal Failure

• Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- SIADH.

CREATININE, SERUM-

Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
 Musde problems, such as breakdown of muscle fibers
- Problem's during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preedampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Múscular dystrophy

URIC ACID, ŚERUM:

Causes of Increased levels Dietary

- High Protein Intake.
- Prolonged Fasting, Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 ĎM.

Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake
- Multiple Sderosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
 Limit animal proteins
- High Fibre foodsVit C Intake





CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDI WHEEL) F-703, F-703, LADO SARAI, MÈHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

AGE: 42 Years ACCESSION NO: 0181VJ000365 SEX: Female ABHA NO:

RECEIVED: 08/10/2022 09:00:07 12/10/2022 16:09:31 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u> Final</u>

· Antioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and alobulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic dearance, malnutrition and wasting etc. ELECTROLYTES (NA/K/CL), SERUM-

Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt Chloride is decreased in overhydration, chronic réspiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisónian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of Kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever

Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain m edications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders. Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection.

pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinums while decreased spécific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus.

Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.
Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

THYROID PANEL, SERUMTriiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is

hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.
In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the quidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

TOTAL T4 TOTAL TŠ Levels in TSH3Ġ (μIU/mL) 0.1 - 2.5 0.2 - 3.0 (ng/dL) 81 - 190 100 - 260 Pregnancy (µg/dL) 6.6 - 12.4 6.6 - 15.5 First Trimester 2nd Trimester 6.6 - 15.5 0.3 - 3.0 3rd Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3 (µg/dL) 1-3 day: 8.2 - 19.9 (ng/dL) New Born: 75 - 260 1 Week: 6.0 - 15.9

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well

documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.





CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: CHAUDHARI MANISHA S

PATIENT ID: CHAUF180280181

ACCESSION NO: 0181VJ000365 AGE: 42 Years SEX: Female ABHA NO:

RECEIVED: 08/10/2022 09:00:07 12/10/2022 16:09:31 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.

2. Gowenhote R.H. Variety's Practical Clinical Biochemistry, but Edition.
3. Behrman R.E. Killegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

